<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25665" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Neonatal Hypoglycemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Abramowski</surname>
            <given-names>Ashley</given-names>
          </name>
          <aff>Palms West Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ward</surname>
            <given-names>Rebecca</given-names>
          </name>
          <aff>University of Florida</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hamdan</surname>
            <given-names>Ashraf H.</given-names>
          </name>
          <aff>Tristar Women's and Children's Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ashley Abramowski declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rebecca Ward declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ashraf Hamdan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>9</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25665.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hypoglycemia is the most common metabolic disturbance occurring in the neonatal period. Screening at-risk infants and the management of low blood glucose levels in the first hours to days of life is a frequent issue in the care of the newborn infant. Yet, a clear definition of neonatal hypoglycemia is lacking. Current screening guidelines and management algorithms are based on limited evidence, relying more on expert opinion to guide recommendations. This activity reviews neonatal hypoglycemia and the need to develop an improved knowledge of it. This activity highlights the role of the interprofessional team in the recognition and management of neonatal hypoglycemia.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the features of neonatal hypoglycemia.</p></list-item><list-item><p>Describe current guidelines for the management of neonatal hypoglycemia.</p></list-item><list-item><p>Review how current knowledge regarding neonatal hypoglycemia could be clarified.</p></list-item><list-item><p>Explain the role of interprofessional team members in optimizing collaboration and communication to ensure neonatal hypoglycemia is recognized early and every effort is made to deliver optimal care, which will lead to enhanced outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25665&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25665">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25665.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hypoglycemia is the most common metabolic disturbance occurring in the neonatal period. Screening at-risk infants and the management of low blood glucose levels in the first hours to days of life is a frequent&#x000a0;issue in the care of the newborn infant. Yet, a clear definition of&#x000a0;neonatal hypoglycemia is lacking.<xref ref-type="bibr" rid="article-25665.r1">[1]</xref><xref ref-type="bibr" rid="article-25665.r2">[2]</xref><xref ref-type="bibr" rid="article-25665.r3">[3]</xref> Current screening guidelines and management algorithms are based&#x000a0;on limited evidence, relying more on expert opinion to guide recommendations.<xref ref-type="bibr" rid="article-25665.r1">[1]</xref><xref ref-type="bibr" rid="article-25665.r3">[3]</xref><xref ref-type="bibr" rid="article-25665.r4">[4]</xref></p>
        <p>Despite a better understanding of early glucose homeostasis and transitional hypoglycemia in the first 48 hours of life, gaps in our knowledge persist. Observations have shown that healthy infants experience transient&#x000a0;hypoglycemia as a part of the&#x000a0;normal&#x000a0;adaption to extrauterine life, with&#x000a0;a&#x000a0;decline&#x000a0;in blood glucose concentrations to values as low as 20 to 25 mg/dL in the first two hours of life.<xref ref-type="bibr" rid="article-25665.r1">[1]</xref> However, because&#x000a0;we do not routinely measure blood glucose concentrations in healthy infants without risk factors for hypoglycemia, it is difficult to define 'normal'&#x000a0;levels of blood glucose in the first 48 hours of life.&#x000a0;As Harding et al. question: "even if healthy infants experience low glucose concentrations, can we extend these values to infants at risk of impaired metabolic adaption?"<xref ref-type="bibr" rid="article-25665.r5">[5]</xref> And how low is too low?&#x000a0;</p>
        <p>A 1988 multicenter nutritional study by Lucas et al. suggested a blood glucose concentration &#x0003c;47 mg/dL&#x000a0;as the critical threshold associated with adverse neurodevelopmental outcomes.<xref ref-type="bibr" rid="article-25665.r1">[1]</xref><xref ref-type="bibr" rid="article-25665.r2">[2]</xref><xref ref-type="bibr" rid="article-25665.r5">[5]</xref><xref ref-type="bibr" rid="article-25665.r6">[6]</xref> The study looked at blood glucose levels in 661 preterm infants with a&#x000a0;birth weight of &#x0003c;1850 grams enrolled in a nutritional study investigating early feeding strategies and cognitive outcomes.<xref ref-type="bibr" rid="article-25665.r1">[1]</xref><xref ref-type="bibr" rid="article-25665.r6">[6]</xref> Investigators found that the number of days of blood glucose concentrations &#x0003c;47 mg/dL&#x000a0;associated with&#x000a0;lower motor and mental developmental scores on the Bayley Scales of Infant Development at 18 months corrected age.<xref ref-type="bibr" rid="article-25665.r6">[6]</xref> Infants that experienced hypoglycemia (glucose &#x0003c;47 mg/dL) on 5 or greater days had 3 to 5 times increased risk of neurodevelopmental impairment.<xref ref-type="bibr" rid="article-25665.r6">[6]</xref> The authors concluded that "even moderate hypoglycemia is associated with a considerable increase in adverse neurodevelopmental sequelae" and&#x000a0;called for a reevaluation of the then current practice trends. As a result,&#x000a0;this value of '47 mg/dL' became widely accepted as the standard numerical value to define neonatal hypoglycemia for all infants, even healthy, term, appropriate for gestational age infants.<xref ref-type="bibr" rid="article-25665.r1">[1]</xref></p>
        <p>It is clear that extremely low blood glucose concentrations in neonates can cause apnea, irritability, lethargy, seizures,<xref ref-type="bibr" rid="article-25665.r7">[7]</xref><xref ref-type="bibr" rid="article-25665.r8">[8]</xref>&#x000a0;and brain damage&#x000a0;<xref ref-type="bibr" rid="article-25665.r9">[9]</xref>; and that prolonged or symptomatic hypoglycemia may correlate with long-term neurodevelopmental deficits.<xref ref-type="bibr" rid="article-25665.r1">[1]</xref><xref ref-type="bibr" rid="article-25665.r10">[10]</xref> However, the long-term significance of early, asymptomatic and transiently low glucose levels remain not well established. And the evidence to support a clear numerical value of blood glucose that is associated with brain injury&#x000a0;or reliably predicts adverse neurodevelopmental outcomes is lacking.<xref ref-type="bibr" rid="article-25665.r3">[3]</xref><xref ref-type="bibr" rid="article-25665.r2">[2]</xref> Even Lucas et al. acknowledged that 'the association between [blood glucose concentrations &#x0003c;47 mg/dL] and poor neurodevelopmental outcomes might not be causal and might reflect a failure&#x000a0;to adjust for confounding&#x000a0;factors.'<xref ref-type="bibr" rid="article-25665.r6">[6]</xref></p>
      </sec>
      <sec id="article-25665.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Healthy infants experience an expected drop in blood glucose concentrations immediately following birth as a part of the normal physiologic transition to extrauterine life. Abruptly clamping the umbilical cord at birth disrupts the infant's connection to the placenta,&#x000a0;upon which it relied&#x000a0;to supply glucose and&#x000a0;other metabolites necessary to meet its energy needs in&#x000a0;utero. The continuous supply of&#x000a0;exogenous intravenous glucose from the placenta suddenly ceases, and the infant's blood glucose&#x000a0;concentration declines in the first hours of life. For most healthy infants, this transitional neonatal hypoglycemia is brief, transient and most often asymptomatic.<xref ref-type="bibr" rid="article-25665.r4">[4]</xref><xref ref-type="bibr" rid="article-25665.r11">[11]</xref></p>
        <p>Infants are at risk&#x000a0;for more severe or prolonged hypoglycemia due to one or a combination of the following underlying mechanisms: insufficient glucose supply, with&#x000a0;low glycogen or fat stores or poor mechanisms of glucose production; increased glucose utilization&#x000a0;caused by excessive insulin production or increased metabolic demand; or the failure of counter-regulatory mechanisms (i.e., pituitary or adrenal failure).<xref ref-type="bibr" rid="article-25665.r12">[12]</xref><xref ref-type="bibr" rid="article-25665.r11">[11]</xref> Neonatal hypoglycemia most commonly&#x000a0;affects the following groups of infants&#x000a0;<xref ref-type="bibr" rid="article-25665.r3">[3]</xref>:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Intrauterine growth restriction or small compared to gestational age infants&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Infants of diabetic mothers or large for gestational age infants&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Late-preterm infants (34 to&#x000a0;36.6 weeks gestational age)&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>Preterm, intrauterine growth restricted and small for gestational age infants are at risk for hypoglycemia because they are born with decreased glycogen stores, decreased adipose tissue and experience increased metabolic demands because of their relatively large brain size.<xref ref-type="bibr" rid="article-25665.r1">[1]</xref><xref ref-type="bibr" rid="article-25665.r12">[12]</xref> In very&#x000a0;low birth weight (&#x0003c;1000 g) preterm infants, the enzymes involved in gluconeogenesis&#x000a0;are expressed at low levels; thus&#x000a0;their ability to&#x000a0;produce endogenous&#x000a0;glucose is poor, contributing to their risk of&#x000a0;severe or prolonged low glucose concentrations.<xref ref-type="bibr" rid="article-25665.r12">[12]</xref></p>
        <p>Infants of diabetic mothers (IDM) and large for gestational age infants experience fetal hyperinsulinism and increased peripheral glucose utilization, putting them at risk for hypoglycemia in the immediate postnatal period.<xref ref-type="bibr" rid="article-25665.r1">[1]</xref><xref ref-type="bibr" rid="article-25665.r4">[4]</xref><xref ref-type="bibr" rid="article-25665.r12">[12]</xref> The placenta supplies the fetus with a direct source of glucose via facilitated diffusion, such that fetal glucose concentrations are proportional to maternal levels. Prolonged elevations in maternal glucose concentrations result in fetal hyperglycemia and pancreatic overstimulation to increase endogenous fetal insulin production.<xref ref-type="bibr" rid="article-25665.r12">[12]</xref>These elevated levels of fetal insulin persist after birth and, in the absence of a continuous exogenous glucose source, result in increased glucose utilization and lower blood glucose concentrations.<xref ref-type="bibr" rid="article-25665.r12">[12]</xref> IDM have a decreased ability to mobilize glycogen stores after birth and experience a relative adrenal insufficiency with decreased levels of catecholamines, further contributing to the risk of low blood glucose levels.</p>
        <p>Infants experiencing perinatal stress (e.g., fetal distress, perinatal ischemia, maternal preeclampsia/eclampsia, sepsis, hypothermia) or those with congenital heart disease have increased metabolic energy requirements, which puts them at risk for hypoglycemia.<xref ref-type="bibr" rid="article-25665.r1">[1]</xref><xref ref-type="bibr" rid="article-25665.r4">[4]</xref><xref ref-type="bibr" rid="article-25665.r12">[12]</xref> Perinatal stress&#x000a0;causes a state of 'hypoglycemic hyperinsulinism'&#x000a0;that can persist for days to weeks, resulting in persistently low glucose concentrations requiring ongoing interventions to maintain euglycemia.<xref ref-type="bibr" rid="article-25665.r1">[1]</xref></p>
        <p>Other iatrogenic causes of transient neonatal hypoglycemia include intrapartum administration of maternal medication (e.g., beta-adrenergic tocolytic agents, valproic acid, propranolol, and conduction anesthetics), delayed feeding, and exogenous insulin administration.<xref ref-type="bibr" rid="article-25665.r12">[12]</xref><xref ref-type="bibr" rid="article-25665.r11">[11]</xref></p>
        <p>Low glucose concentrations beyond the first 48 hours of life raise concern for an underlying disorder as the etiology of hypoglycemia. The underlying physiologic mechanisms that cause pathologic or persistent hypoglycemia are similar to those described above: hyperinsulinism (e.g., congenital hyperinsulinism, Beckwith-Wiedmann syndrome, Soto syndrome), insufficient energy supply (i.e., inborn errors of metabolism that result in deficiencies in glycogen, amino acids, or free fatty acids), or a deficiency in cortisol or growth hormone (e.g., Costello syndrome, hypopituitarism, congenital adrenal hyperplasia). Causes of persistent neonatal hypoglycemia include <xref ref-type="bibr" rid="article-25665.r12">[12]</xref><xref ref-type="bibr" rid="article-25665.r10">[10]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Congenital hyperinsulinism&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Congenital&#x000a0;syndromes: Beckwith-Wiedemann syndrome, Soto syndrome, Costello syndrome&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Endocrine disorders: congenital hypopituitarism, congenital adrenal hyperplasia, hypothyroidism&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Inborn errors of metabolism: maple syrup urine disease, glycogen storage disorders, hereditary fructose intolerance, galactosemia, fatty acid oxidation disorders</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25665.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The&#x000a0;reported incidence of neonatal hypoglycemia is variable, depending on several factors: the population of infants included, the frequency and timing of glucose testing, the method of testing, and the definition of hypoglycemia used. A 2006 study by Harris&#x000a0;et al.&#x000a0;that sought to determine the incidence of hypoglycemia (blood glucose &#x0003c;47 mg/dL) in the first 48 hours of life in infants greater than 35 weeks gestation at risk of hypoglycemia by AAP guidelines found that 25% of all deliveries&#x000a0;were&#x000a0;at risk for hypoglycemia; of those at-risk infants, 51% experienced at least one episode of hypoglycemia.<xref ref-type="bibr" rid="article-25665.r1">[1]</xref><xref ref-type="bibr" rid="article-25665.r13">[13]</xref></p>
      </sec>
      <sec id="article-25665.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The fetus depends on maternal metabolism and placental circulation to provide the glucose, ketones, free fatty acids, and amino acids necessary to meet its energy requirements.<xref ref-type="bibr" rid="article-25665.r2">[2]</xref> The placenta supplies fetal circulation with a direct source of glucose.<xref ref-type="bibr" rid="article-25665.r2">[2]</xref><xref ref-type="bibr" rid="article-25665.r5">[5]</xref> Clamping the umbilical cord at birth abruptly disrupts this continuous source of glucose, resulting in a rapid decline in blood glucose levels in the first 2 to 3 hours of life.<xref ref-type="bibr" rid="article-25665.r1">[1]</xref><xref ref-type="bibr" rid="article-25665.r2">[2]</xref><xref ref-type="bibr" rid="article-25665.r5">[5]</xref> Low blood glucose concentrations cause a surge&#x000a0;of insulin and other hormones (including catecholamines, glucagon, and corticosteroids) that stimulate glucose production via gluconeogenesis and glycogenolysis and enhance fatty acid oxidation. This provides the infant with an endogenous source of glucose and other energy substrates necessary to sustain its metabolism <xref ref-type="bibr" rid="article-25665.r1">[1]</xref>; the result is the gradual rise of blood glucose levels over the next several hours to days.<xref ref-type="bibr" rid="article-25665.r5">[5]</xref> Low glucose&#x000a0;levels are also thought to stimulate the neonate&#x02019;s appetite and help the neonate adapt to intermittent feeds.<xref ref-type="bibr" rid="article-25665.r1">[1]</xref></p>
        <p>Any mechanism that disrupts this sequence of physiologic changes puts the infant at risk of more severe or prolonged periods of low glucose. The risk for&#x000a0;hypoglycemia is greatest in the first hours after birth.<xref ref-type="bibr" rid="article-25665.r5">[5]</xref><xref ref-type="bibr" rid="article-25665.r12">[12]</xref></p>
        <p>Persistent hypoglycemia&#x000a0;results from excessive insulin secretion, a deficiency of cortisol or growth hormone, or inborn errors of metabolism.<xref ref-type="bibr" rid="article-25665.r4">[4]</xref><xref ref-type="bibr" rid="article-25665.r12">[12]</xref></p>
      </sec>
      <sec id="article-25665.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The clinical presentation of neonatal hypoglycemia is variable. An otherwise healthy infant may remain asymptomatic despite extremely low blood glucose levels during the period of transitional hypoglycemia. Clinical symptoms do not correlate with blood glucose levels.</p>
        <p>Symptoms of neonatal hypoglycemia include <xref ref-type="bibr" rid="article-25665.r2">[2]</xref><xref ref-type="bibr" rid="article-25665.r11">[11]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Sweating&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Feeding difficulties, poor suck&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Weak or high-pitched cry&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Tremors</p>
          </list-item>
          <list-item>
            <p>Hypothermia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Irritability&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Lethargy/stupor&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hypotonia</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Coma</p>
          </list-item>
          <list-item>
            <p>Apnea, grunting or tachypnea&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cyanosis&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25665.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The two major academic societies, the American Academy of Pediatrics (AAP) and the Pediatric Endocrine Society (PES), present conflicting guidelines for screening at-risk infants and the management of neonatal hypoglycemia. The most recent AAP guidelines&#x000a0;recommend screening for late preterm and term infants that experience symptoms of hypoglycemia, and asymptomatic infants at&#x000a0;highest risk for hypoglycemia in the first 12 to 24 hours of life. "At risk" infants include late preterm (34-36.6 weeks gestation), term infants who are small for gestational age, infants of diabetic mothers, and large for gestational age infants.<xref ref-type="bibr" rid="article-25665.r3">[3]</xref> The guidelines state that&#x000a0;'routine screening and monitoring of blood glucose is not needed in healthy term infants after a normal pregnancy and delivery.'<xref ref-type="bibr" rid="article-25665.r3">[3]</xref></p>
        <p>The Pediatric Endocrine Society (PES) recommends screening&#x000a0;all infants with risk factors for prolonged or pathologic hypoglycemia, including <xref ref-type="bibr" rid="article-25665.r4">[4]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Symptomatic hypoglycemia</p>
          </list-item>
          <list-item>
            <p>Large for gestational age</p>
          </list-item>
          <list-item>
            <p>Perinatal stress
<list list-type="bullet"><list-item><p>Perinatal hypoxia/ischemia, fetal distress</p></list-item><list-item><p>Maternal pre-eclampsia/eclampsia</p></list-item><list-item><p>Meconium aspiration syndrome, erythroblastosis fetalis, polycythemia, hypothermia</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Premature or post-term delivery</p>
          </list-item>
          <list-item>
            <p>Infant of diabetic mother</p>
          </list-item>
          <list-item>
            <p>Family history of genetic hypoglycemia</p>
          </list-item>
          <list-item>
            <p>Congenital syndrome (e.g., Beckwith-Wiedermann), abnormal physical features (e.g., midline facial malformations)</p>
          </list-item>
        </list>
        <p>Per the PES guidelines, infants unable to&#x000a0;maintain&#x000a0;pre-prandial blood glucose values &#x0003e;50 mg/dL in the first 48 hours of life or &#x0003e;60 mg/dL thereafter are&#x000a0;at risk for persistent hypoglycemia and require further&#x000a0;workup&#x000a0;prior to discharge home.<xref ref-type="bibr" rid="article-25665.r4">[4]</xref> The PES recommends that the evaluation of infants at risk for persistent hypoglycemia for an underlying etiology occur&#x000a0;<italic toggle="yes">after&#x000a0;</italic>the first 48 hours of life, to exclude those infants experiencing transient low glucose levels (i.e., transitional neonatal hypoglycemia).<xref ref-type="bibr" rid="article-25665.r4">[4]</xref></p>
        <p>The PES recommends&#x000a0;evaluation of the following infants to exclude persistent causes of hypoglycemia <xref ref-type="bibr" rid="article-25665.r4">[4]</xref>:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Symptomatic hypoglycemia or severe hypoglycemia requiring treatment with intravenous dextrose&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Infants unable to maintain blood glucose concentrations &#x0003e;50 mg/dL&#x000a0;in the first 48 hours of life and &#x0003e;60 after 48 hours of age&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Family history of a genetic form of hypoglycemia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Congenital syndrome (e.g., Beckwith-Wiedermann), abnormal physical features (e.g., midline facial malformations)</p>
          </list-item>
        </list>
        <p>Point-of-care testing&#x000a0;(POCT)&#x000a0;offers a&#x000a0;quick and cost-effective method for screening for hypoglycemia.<xref ref-type="bibr" rid="article-25665.r5">[5]</xref> However, these methods have limitations. Most standard instruments use non-enzymatic methods to measure blood glucose concentration,&#x000a0;which are less accurate at lower glucose values than laboratory analysis using glucose oxidase methods (the gold standard).<xref ref-type="bibr" rid="article-25665.r5">[5]</xref> Whole blood samples (used in POCT) have&#x000a0;10% to 18% lower glucose concentrations than plasma, depending on the&#x000a0;hematocrit.<xref ref-type="bibr" rid="article-25665.r5">[5]</xref> Therefore, abnormally low glucose values on POCT require confirmation by measuring plasma glucose concentration using clinical laboratory methods.<xref ref-type="bibr" rid="article-25665.r4">[4]</xref><xref ref-type="bibr" rid="article-25665.r10">[10]</xref></p>
        <p>More recently, the&#x000a0;use of continuous glucose&#x000a0;monitoring (CGM) in&#x000a0;the detection and management of neonatal hypoglycemia is under investigation. A study published in 2010 by Harris et al.&#x000a0;looked at the usefulness of continuous glucose monitoring in 102 infants &#x0003e;32 weeks gestation&#x000a0;at risk of hypoglycemia during the first 7 days of life.<xref ref-type="bibr" rid="article-25665.r14">[14]</xref> Infants&#x000a0;were&#x000a0;screened&#x000a0;for hypoglycemia with intermittent&#x000a0;blood glucose&#x000a0;measurements and started on early oral feeds or intravenous dextrose solution per clinical guidelines.<xref ref-type="bibr" rid="article-25665.r14">[14]</xref> Investigators found that detected hypoglycemia (blood glucose &#x0003c;47 mg/dL) was present in 44% of infants using continuous glucose monitoring, versus 32% of infants with intermittent blood glucose sampling.<xref ref-type="bibr" rid="article-25665.r14">[14]</xref> And that there is good agreement between interstitial (used in continuous monitoring) and blood glucose measurements.<xref ref-type="bibr" rid="article-25665.r14">[14]</xref> The study suggests that continuous glucose monitoring is a safe, easy to use, and detects more episodes of hypoglycemia.<xref ref-type="bibr" rid="article-25665.r14">[14]</xref></p>
        <p>In infants with&#x000a0;persistent hypoglycemia suspected of having an underlying disorder, measuring bicarbonate, lactic acid,&#x000a0;beta-hydroxybutyrate, free fatty acids, insulin and carnitine levels during hypoglycemia (blood glucose &#x0003c;50 mg/dL)&#x000a0;is useful in differentiating between the metabolic causes of persistent hypoglycemia and aids in the diagnosis of hyperinsulinism and disorders of fatty acid oxidation.<xref ref-type="bibr" rid="article-25665.r4">[4]</xref></p>
      </sec>
      <sec id="article-25665.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>In the absence of a consistent definition of neonatal hypoglycemia, recommendations differ as to the lower level of glucose that is acceptable and when intervention is necessary. Though strategies focus on target glucose concentrations, the ultimate&#x000a0;goal of management&#x000a0;is to reduce the risk of brain injury and long-term neurodevelopmental&#x000a0;deficits that may correlate with hypoglycemia.<xref ref-type="bibr" rid="article-25665.r5">[5]</xref></p>
        <p>Early initiation of breastfeeding is&#x000a0;crucial for all infants.&#x000a0;For asymptomatic infants at risk of neonatal hypoglycemia, the AAP recommends initiating feeds within the <italic toggle="yes">first</italic> hour of life and performing&#x000a0;initial glucose screening 30 minutes after the first feed.<xref ref-type="bibr" rid="article-25665.r3">[3]</xref> The AAP recommends goal blood glucose levels equal to or greater than 45 mg/dL prior to routine feedings, and intervention for blood glucose &#x0003c;40 mg/dL&#x000a0;in the first 4 hours of life and &#x0003c;45 mg/dL&#x000a0;at 4 to 24 hours of life.<xref ref-type="bibr" rid="article-25665.r1">[1]</xref><xref ref-type="bibr" rid="article-25665.r3">[3]</xref> The best intervention for asymptomatic hypoglycemia is to increase feeding frequency.<xref ref-type="bibr" rid="article-25665.r5">[5]</xref> Increasing breastfeeding is challenging for some infants. Difficulties with infant latching, poor feeding, and low volumes of breast-milk may interfere with the successful establishment of early breastfeeding in the first hours of life. Most commonly, infant formula is the choice for asymptomatic neonatal hypoglycemia in late preterm and term infants.<xref ref-type="bibr" rid="article-25665.r5">[5]</xref> Formula is inexpensive, readily available, easy to give, and has a high carbohydrate content, resulting in a rapid rise&#x000a0;of blood glucose concentrations within minutes.<xref ref-type="bibr" rid="article-25665.r12">[12]</xref> However, the use of infant formula risks interrupting establishment of breastfeeding and alters the neonatal microbiome, potentially increasing the risk&#x000a0;of infections and allergies.<xref ref-type="bibr" rid="article-25665.r5">[5]</xref> Blood glucose levels should be re-checked one hour after feeding.&#x000a0;It is uncertain whether early episodes of low glucose in the first 48 hours of life need correction in asymptomatic, healthy infants without risk factors for hypoglycemia.<xref ref-type="bibr" rid="article-25665.r5">[5]</xref><xref ref-type="bibr" rid="article-25665.r3">[3]</xref></p>
        <p>Dextrose&#x000a0;gel 200 mg/kg massaged into the buccal mucosa is&#x000a0;an effective treatment alternative in asymptomatic late preterm and term infants.<xref ref-type="bibr" rid="article-25665.r5">[5]</xref><xref ref-type="bibr" rid="article-25665.r12">[12]</xref> Dextrose gel is relatively inexpensive, well tolerated, and its use&#x000a0;has&#x000a0;been shown to decrease admissions to neonatal intensive care unit for intravenous dextrose.<xref ref-type="bibr" rid="article-25665.r5">[5]</xref> Additionally, the use of dextrose gel may be a more advantageous&#x000a0;treatment option over infant formula because it promotes breastfeeding and maternal-infant bonding.&#x000a0;</p>
        <p>The AAP recommends admission to the neonatal intensive care unit and intervention with intravenous dextrose for the following<xref ref-type="bibr" rid="article-25665.r3">[3]</xref>:</p>
        <p>All symptomatic infants with a glucose level less than 40 mg/dL</p>
        <p>Infants with persistent hypoglycemia despite&#x000a0;increased feeding frequency</p>
        <p>***Asymptomatic at-risk infants with extremely low&#x000a0;blood glucose concentrations &#x0003c;25 mg/dL&#x000a0;in the first 4 hours of life or &#x0003c;35 mg/dL&#x000a0;at 4 to 24 hours of life.</p>
        <p>Intravenous glucose is&#x000a0;given as a bolus of 200 mg/kg (dextrose 10% at 2 mL/kg), followed by continuous infusion of dextrose 10% at 5 to 8 mg/kg per minute (80 to 100 mL/kg per day) to maintain blood glucose levels of 40 to 50 mg/dL.<xref ref-type="bibr" rid="article-25665.r1">[1]</xref><xref ref-type="bibr" rid="article-25665.r3">[3]</xref> Infants on intravenous dextrose infusions require close monitoring with frequent measurements of blood glucose levels, as often as every hour for the first 12 hours, then less frequently one target glucose&#x000a0;values&#x000a0;are achieved.<xref ref-type="bibr" rid="article-25665.r12">[12]</xref> In infants of diabetic mothers, lower glucose infusions rates of 3 to 5 mg/kg/minute may be used&#x000a0;to minimize pancreatic stimulation and endogenous insulin secretion.<xref ref-type="bibr" rid="article-25665.r12">[12]</xref> Infants requiring higher rates of intravenous dextrose (&#x0003e;12 to 16 mg/kg/minute) or for more than 5 days are more likely to have a persistent cause of hypoglycemia.<xref ref-type="bibr" rid="article-25665.r12">[12]</xref></p>
        <p>Second-line therapies for the treatment of persistent hypoglycemia include the use of corticosteroids or glucagon.<xref ref-type="bibr" rid="article-25665.r12">[12]</xref>Corticosteroids increased blood glucose concentrations by decrease peripheral utilization of glucose and are given as hydroxycortisone&#x000a0;5 to 15 mg/kg per day or prednisone 2 mg/kg per day.<xref ref-type="bibr" rid="article-25665.r12">[12]</xref> Glucagon is a hormone that stimulates endogenous glucose production via glycogenolysis and gluconeogenesis; thus its effectiveness depends on the infant having adequate glycogen stores.<xref ref-type="bibr" rid="article-25665.r12">[12]</xref> It is most useful in term infants and infants of diabetic mothers.<xref ref-type="bibr" rid="article-25665.r12">[12]</xref> Glucagon dosing is as a 30 mcg/kg bolus or 300 mcg/kg per minute continuous infusion.<xref ref-type="bibr" rid="article-25665.r12">[12]</xref></p>
        <p>The PES recommends&#x000a0;target glucose concentrations &#x0003e;50 mg/dL for infants at risk of hypoglycemia without a suspected congenital disorder during the first 48 hours of life, and &#x0003e;60 mg/dL thereafter.<xref ref-type="bibr" rid="article-25665.r4">[4]</xref> Infants unable to maintain these glucose targets despite regular feedings schedule should be evaluated&#x000a0;to exclude a persistent cause of hypoglycemia prior to discharge home to ensure early recognition and facilitate treatment.<xref ref-type="bibr" rid="article-25665.r4">[4]</xref></p>
        <p>For infants with persistent hypoglycemia, the goal of management in infants with suspected&#x000a0;hyperinsulinism&#x000a0;is to prevent recurrent&#x000a0;episodes of low blood glucose&#x000a0;levels that&#x000a0;put the infant at risk for future episodes of hypoglycemia. For neonates with inborn errors of metabolism and impaired endogenous glucose production, the goal of management is to prevent metabolic acidosis and subsequent growth failure.<xref ref-type="bibr" rid="article-25665.r4">[4]</xref> The Pediatric Endocrine Society&#x000a0;recommends&#x000a0;giving endogenous glucose to keep blood glucose levels&#x000a0;&#x0003e;70 mg/dL in these infants. Diazoxide&#x000a0;infusions of 10 to 15 mg/kg per day may be used in infants with congenital hyperinsulinism to inhibit insulin secretions; effects&#x000a0;are seen within 2 to 4 days.<xref ref-type="bibr" rid="article-25665.r12">[12]</xref> Recommendations call for early&#x000a0;consultation&#x000a0;with endocrinology or&#x000a0;genetics.<xref ref-type="bibr" rid="article-25665.r4">[4]</xref></p>
      </sec>
      <sec id="article-25665.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The symptoms of neonatal hypoglycemia are nonspecific and&#x000a0;overlap with symptoms of other conditions, including prematurity, sepsis, hypoxic-ischemic encephalopathy and hyponatremia. As discussed above, though rare, persistent&#x000a0;causes of hypoglycemia&#x000a0;must be excluded.&#x000a0;</p>
      </sec>
      <sec id="article-25665.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The&#x000a0;implications of asymptomatic hypoglycemia in the first 48 hours of life&#x000a0;on long-term neurodevelopmental outcomes remains bot well established. As a result of an influential study published in 1988 by Lucas et al. suggesting that recurrent, moderate neonatal hypoglycemia&#x000a0;correlated with serious motor and mental impairments at 18 months corrected age,<xref ref-type="bibr" rid="article-25665.r6">[6]</xref> it was&#x000a0;accepted that even early, asymptomatic hypoglycemia could&#x000a0;harm long-term development.<xref ref-type="bibr" rid="article-25665.r2">[2]</xref><xref ref-type="bibr" rid="article-25665.r15">[15]</xref> Several other observational studies&#x000a0;presented similar conclusions.&#x000a0;However, it is difficult to prove causation in observed outcomes. Contributing to the challenge in understanding the effects of low glucose levels, most studies have failed&#x000a0;to include euglycemia controls and use variable definitions of 'hypoglycemia.'<xref ref-type="bibr" rid="article-25665.r2">[2]</xref>&#x000a0;A 2006 systematic review assessing the evidence of neonatal hypoglycemia on neurodevelopmental outcomes by&#x000a0;Boluyt et al.&#x000a0;found that a majority of studies&#x000a0;were of overall poor quality and that the results of the two high-quality studies were invalid because of heterogeneity&#x000a0;in methods.<xref ref-type="bibr" rid="article-25665.r2">[2]</xref><xref ref-type="bibr" rid="article-25665.r16">[16]</xref> The authors' conclusion was that none of the studies provided valid evidence of the effects of neonatal hypoglycemia on neurodevelopment on which to make clinical recommendations&#x000a0;and called for&#x000a0;a well-designed, prospective study on this topic.<xref ref-type="bibr" rid="article-25665.r16">[16]</xref></p>
        <p>Despite&#x000a0;requests for further research of&#x000a0;infants at risk of hypoglycemia with long-term neurodevelopmental follow up,<xref ref-type="bibr" rid="article-25665.r17">[17]</xref><xref ref-type="bibr" rid="article-25665.r18">[18]</xref> there have only been two studies that&#x000a0;meet the methodological criteria recommended by&#x000a0;Boluyt et al.: A 15-year follow-up study of recurrent hypoglycemia in preterm infants by Tin et al.<xref ref-type="bibr" rid="article-25665.r15">[15]</xref> and The Children with Hypoglycemia and Their Later Development (CHYLD) study.<xref ref-type="bibr" rid="article-25665.r5">[5]</xref><xref ref-type="bibr" rid="article-25665.r19">[19]</xref> Published in 2012, the Tin et al. study sought to confirm the findings of the 1988 Lucas et al. study.<xref ref-type="bibr" rid="article-25665.r6">[6]</xref>This prospective study&#x000a0;included preterm infants &#x0003c;32 weeks gestation born between 1990 and 1991 who had blood glucose measurements taken in the first 10 days of life.<xref ref-type="bibr" rid="article-25665.r15">[15]</xref> Investigators matched infants that had experienced recurrent&#x000a0;neonatal hypoglycemia (defined as blood glucose &#x0003c;47 mg/dL on 3 or&#x000a0;more days in the first 10 days of life) with euglycemia controls and&#x000a0;found no differences&#x000a0;in development or physical disability at age 2 years.<xref ref-type="bibr" rid="article-25665.r2">[2]</xref><xref ref-type="bibr" rid="article-25665.r15">[15]</xref> On reassessment at age 15 years, investigators again found no difference in development or IQ scores between the two groups.<xref ref-type="bibr" rid="article-25665.r15">[15]</xref> The authors concluded that the "study found no evidence to support the belief that recurrent low blood glucose levels in the first 10 days of life usually pose a hazard to preterm infants".<xref ref-type="bibr" rid="article-25665.r15">[15]</xref></p>
        <p>The CHYLD study is a prospective cohort investigation of infants born &#x0003e;32 weeks gestation with risk factors for neonatal hypoglycemia.<xref ref-type="bibr" rid="article-25665.r19">[19]</xref> The initial findings showed that&#x000a0;treatment of neonatal hypoglycemia to&#x000a0;maintain blood glucose &#x0003e;47 mg/dL did not correlate with an increased risk of neurosensory impairment at 4.5 years of age.<xref ref-type="bibr" rid="article-25665.r19">[19]</xref> Infants that experienced more severe or prolonged episodes of low blood glucose did not have worse outcomes.<xref ref-type="bibr" rid="article-25665.r5">[5]</xref><xref ref-type="bibr" rid="article-25665.r19">[19]</xref> Investigators could not establish a numerical glucose level at which risk increased, but found that&#x000a0;glucose instability (the proportion of measurements and duration of time blood glucose values were outside the range of 54 to 72 mg/dL)&#x000a0;in the 48 hours of life was most predictive of worse developmental outcomes.<xref ref-type="bibr" rid="article-25665.r5">[5]</xref><xref ref-type="bibr" rid="article-25665.r19">[19]</xref> Infants with the greatest glucose instability had a 2 to 3-fold increased risk of neurosensory impairment.<xref ref-type="bibr" rid="article-25665.r5">[5]</xref><xref ref-type="bibr" rid="article-25665.r19">[19]</xref> Interestingly, moderate "hyperglycemia," blood glucose values &#x0003e;72 mg/dL, did correlate with an increased risk of poor visual motor and executive functioning.<xref ref-type="bibr" rid="article-25665.r19">[19]</xref> This finding raises the question: are infants experiencing low and "high"&#x000a0;early blood glucose values at risk of worse neurodevelopmental outcomes?</p>
      </sec>
      <sec id="article-25665.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Severe, prolonged hypoglycemia in the neonatal period can&#x000a0;have devastating outcomes, including long-term neurodevelopmental disabilities, cerebral palsy, and death.&#x000a0;Infants with congenital causes of persistent hypoglycemia have significantly higher rates of morbidity and mortality: 25 to 50%&#x000a0;have developmental disabilities.<xref ref-type="bibr" rid="article-25665.r4">[4]</xref> Nervous tissue can survive long periods of low blood glucose levels&#x000a0;by utilizing alternative&#x000a0;energy substrates (ketones, amino acids, lactate) to fuel its metabolic demands.<xref ref-type="bibr" rid="article-25665.r4">[4]</xref><xref ref-type="bibr" rid="article-25665.r9">[9]</xref> The hypothesis is that the utilization of these alternative metabolites may have a neuroprotective effect on the immature neonatal brain.<xref ref-type="bibr" rid="article-25665.r11">[11]</xref> Ultimately, however, a glucose supply must be established.&#x000a0;In 1967, Anderson et al. published a case series of the pathologic findings of 6 infants with severe, prolonged hypoglycemia&#x000a0;in&#x000a0;the first week of life.<xref ref-type="bibr" rid="article-25665.r9">[9]</xref> The authors&#x000a0;reported that severe, prolonged hypoglycemia caused extensive degeneration of the central nervous system and, if left untreated, ultimately resulted in death.<xref ref-type="bibr" rid="article-25665.r9">[9]</xref> The brain damage was&#x000a0;less severe in infants treated&#x000a0;with exogenous glucose.<xref ref-type="bibr" rid="article-25665.r9">[9]</xref> Thus, early recognition of conditions that cause persistent hypoglycemia is critical.</p>
      </sec>
      <sec id="article-25665.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Frequent blood glucose screening and the diagnosis of neonatal hypoglycemia can be stressful for new mothers. The&#x000a0;best&#x000a0;management approach is one that promotes mother-infant bonding and early breastfeeding.&#x000a0;</p>
      </sec>
      <sec id="article-25665.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>It is essential that clinicians and nursing staff in the newborn nursery maintain clinical suspicion for neonatal hypoglycemia as symptoms are vague and nonspecific.&#x000a0;For infants at risk for persistent hypoglycemia, it is vital to establish that the infant can maintain blood glucose levels at target range before discharge home, as persistent hypoglycemia may not manifest&#x000a0;clinical symptoms until after the first 48 hours of life, by which time many infants have already been discharged home.&#x000a0;</p>
      </sec>
      <sec id="article-25665.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25665&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25665">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/child-health/neonatal-hypoglycemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25665">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25665/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25665">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25665.s15">
        <title>References</title>
        <ref id="article-25665.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adamkin</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Neonatal hypoglycemia.</article-title>
            <source>Semin Fetal Neonatal Med</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-41</page-range>
            <pub-id pub-id-type="pmid">27605513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tin</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Defining neonatal hypoglycaemia: a continuing debate.</article-title>
            <source>Semin Fetal Neonatal Med</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-32</page-range>
            <pub-id pub-id-type="pmid">24148999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Committee on Fetus and Newborn</collab>
              <name>
                <surname>Adamkin</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Postnatal glucose homeostasis in late-preterm and term infants.</article-title>
            <source>Pediatrics</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>127</volume>
            <issue>3</issue>
            <fpage>575</fpage>
            <page-range>575-9</page-range>
            <pub-id pub-id-type="pmid">21357346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thornton</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Stanley</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>De Leon</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Haymond</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Levitsky</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Rozance</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Wolfsdorf</surname>
                <given-names>JI</given-names>
              </name>
              <collab>Pediatric Endocrine Society</collab>
            </person-group>
            <article-title>Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children.</article-title>
            <source>J Pediatr</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>167</volume>
            <issue>2</issue>
            <fpage>238</fpage>
            <page-range>238-45</page-range>
            <pub-id pub-id-type="pmid">25957977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harding</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Hegarty</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Alsweiler</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>McKinlay</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>An emerging evidence base for the management of neonatal hypoglycaemia.</article-title>
            <source>Early Hum Dev</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>104</volume>
            <fpage>51</fpage>
            <page-range>51-56</page-range>
            <pub-id pub-id-type="pmid">27989586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morley</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Adverse neurodevelopmental outcome of moderate neonatal hypoglycaemia.</article-title>
            <source>BMJ</source>
            <year>1988</year>
            <month>Nov</month>
            <day>19</day>
            <volume>297</volume>
            <issue>6659</issue>
            <fpage>1304</fpage>
            <page-range>1304-8</page-range>
            <pub-id pub-id-type="pmid">2462455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>CORNBLATH</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>ODELL</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>LEVIN</surname>
                <given-names>EY</given-names>
              </name>
            </person-group>
            <article-title>Symptomatic neonatal hypoglycemia associated with toxemia of pregnancy.</article-title>
            <source>J Pediatr</source>
            <year>1959</year>
            <month>Nov</month>
            <volume>55</volume>
            <fpage>545</fpage>
            <page-range>545-62</page-range>
            <pub-id pub-id-type="pmid">13811999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>HAWORTH</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>COODIN</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>FINKEL</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>WEIDMAN</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Hypoglycemia associated with symptoms in the newborn period.</article-title>
            <source>Can Med Assoc J</source>
            <year>1963</year>
            <month>Jan</month>
            <day>05</day>
            <volume>88</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-8</page-range>
            <pub-id pub-id-type="pmid">13953228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Milner</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Strich</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Effects of neonatal hypoglycaemia on the nervous system: a pathological study.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>1967</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>295</fpage>
            <page-range>295-310</page-range>
            <pub-id pub-id-type="pmid">6055339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thompson-Branch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Havranek</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Neonatal Hypoglycemia.</article-title>
            <source>Pediatr Rev</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>147</fpage>
            <page-range>147-157</page-range>
            <pub-id pub-id-type="pmid">28364046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puchalski</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Karlsen</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Neonatal Hypoglycemia: Is There a Sweet Spot?</article-title>
            <source>Crit Care Nurs Clin North Am</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>467</fpage>
            <page-range>467-480</page-range>
            <pub-id pub-id-type="pmid">30447807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shekhawat</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Hypoglycemia in the preterm neonate: etiopathogenesis, diagnosis, management and long-term outcomes.</article-title>
            <source>Transl Pediatr</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>335</fpage>
            <page-range>335-348</page-range>
            <pub-id pub-id-type="pmid">29184814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harris</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Weston</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Incidence of neonatal hypoglycemia in babies identified as at risk.</article-title>
            <source>J Pediatr</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>161</volume>
            <issue>5</issue>
            <fpage>787</fpage>
            <page-range>787-91</page-range>
            <pub-id pub-id-type="pmid">22727868</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harris</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Battin</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Weston</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Continuous glucose monitoring in newborn babies at risk of hypoglycemia.</article-title>
            <source>J Pediatr</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>157</volume>
            <issue>2</issue>
            <fpage>198</fpage>
            <page-range>198-202.e1</page-range>
            <pub-id pub-id-type="pmid">20338573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tin</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Brunskill</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fritz</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>15-year follow-up of recurrent "hypoglycemia" in preterm infants.</article-title>
            <source>Pediatrics</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>130</volume>
            <issue>6</issue>
            <fpage>e1497</fpage>
            <page-range>e1497-503</page-range>
            <pub-id pub-id-type="pmid">23129080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boluyt</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>van Kempen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Offringa</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Neurodevelopment after neonatal hypoglycemia: a systematic review and design of an optimal future study.</article-title>
            <source>Pediatrics</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>117</volume>
            <issue>6</issue>
            <fpage>2231</fpage>
            <page-range>2231-43</page-range>
            <pub-id pub-id-type="pmid">16740869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McKinlay</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Neonatal Glycaemia and Neurodevelopmental Outcomes: A Systematic Review and Meta-Analysis.</article-title>
            <source>Neonatology</source>
            <year>2019</year>
            <volume>115</volume>
            <issue>2</issue>
            <fpage>116</fpage>
            <page-range>116-126</page-range>
            <pub-id pub-id-type="pmid">30408811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hay</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Raju</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Kalhan</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Devaskar</surname>
                <given-names>SU</given-names>
              </name>
            </person-group>
            <article-title>Knowledge gaps and research needs for understanding and treating neonatal hypoglycemia: workshop report from Eunice Kennedy Shriver National Institute of Child Health and Human Development.</article-title>
            <source>J Pediatr</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>155</volume>
            <issue>5</issue>
            <fpage>612</fpage>
            <page-range>612-7</page-range>
            <pub-id pub-id-type="pmid">19840614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25665.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKinlay</surname>
                <given-names>CJD</given-names>
              </name>
              <name>
                <surname>Alsweiler</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Anstice</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Burakevych</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chakraborty</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chase</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Gamble</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Paudel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>San Diego</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wouldes</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>JE</given-names>
              </name>
              <collab>Children With Hypoglycemia and Their Later Development (CHYLD) Study Team</collab>
            </person-group>
            <article-title>Association of Neonatal Glycemia With Neurodevelopmental Outcomes at 4.5 Years.</article-title>
            <source>JAMA Pediatr</source>
            <year>2017</year>
            <month>Oct</month>
            <day>01</day>
            <volume>171</volume>
            <issue>10</issue>
            <fpage>972</fpage>
            <page-range>972-983</page-range>
            <pub-id pub-id-type="pmid">28783802</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
